Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.
Deepa Jagadeesh, MD, associate staff, Department of Hematologic Oncology and Blood Disorders, Lymphoma and Bone Marrow Transplant Programs, Cleveland Clinic, discusses unmet needs in aggressive and rare lymphoma subtypes.
Most available therapies in relapsed/refractory peripheral T-cell lymphoma (PTCL) elicit response rates around 30%, which represents a major unmet need in the space, Jagadeesh says.
Notably, duvelisib (Copiktra) has demonstrated slightly higher historical response rates in patients with relapsed/refractory PTCL, Jagadeesh says. Moreover, brentuximab vedotin (Adcetris) has shown encouraging response rates in patients with anaplastic large cell lymphoma.
Despite this, few treatment options are available for patients with rare lymphoma subtypes because it is difficult to enroll them onto clinical trials, Jagadeesh explains. This can be true even if the patient is eligible for enrollment.
As such, additional data are needed to draw meaningful conclusions regarding the efficacy of novel therapies in this space, Jagadeesh concludes.